Justice Department Recovers $2 Billion for Fraud Against the Government in Fy 2007; More Than $20 Billion Since 1986

WASHINGTON -- The United States obtained $2 billion in settlements and judgments
in the fiscal year ending September 30, 2007, pursuing allegations of fraud
against the federal government, the Justice Department announced today. This
brings total recoveries since 1986, when Congress substantially strengthened the
civil False Claims Act, to more than $20 billion.

“This year's outstanding recoveries in civil fraud cases demonstrate this
administration's unwavering commitment to root out fraud against the government
and to ensure that citizens' tax dollars are well spent,” said Peter D. Keisler,
Acting Attorney General and Assistant Attorney General for the Civil Division.
“It also attests to the fortitude of whistleblowers who report fraud and the
tireless efforts of the civil servants who investigate and prosecute these
cases.”

Mr. Keisler also paid tribute to Senator Charles Grassley of Iowa and
Representative Howard L. Berman of California, who sponsored the 1986 amendments
to the False Claims Act, the government's primary weapon to fight fraud against
the government. “Without this important legislation strengthening the Act and,
in particular, the qui tam provisions which give ordinary citizens the courage
and protection to blow the whistle on those who defraud the government, such
recoveries would not have been possible."

Of the $2 billion, $1.45 billion is associated with suits initiated by
whistleblowers under the False Claims Act's qui tam provisions. These
whistleblower provisions authorize individuals, known as "relators," to file
suit on behalf of the United States against those who have falsely or
fraudulently claimed federal funds. Such cases run the gamut of federally funded
programs from
Medicare and Medicaid to defense procurement contracts, disaster assistance
loans, and agricultural subsidies. Persons who knowingly make false claims for
federal funds are liable for three times the government’s loss plus a civil
penalty of $5,500 to $11,000 for each claim. Relators recover 15 to 25 percent
of the proceeds of a successful suit if the United States intervenes in the qui
tam action, and up to 30 percent if the United States declines and the relator
pursues the action alone. In fiscal year 2007, whistleblowers were awarded $177
million. (This figure does not include relator shares for fiscal year 2007
which have not yet been awarded or were awarded after September 30, 2007.)

As in the last several years, health care accounted for the lion's share of
fraud settlements and judgments–$1.54 billion. This number includes both
whistleblower claims and those initiated by the United States in independent
fraud investigations. Cases involving fraud against the Department of Health and
Human Services reaped the biggest recoveries, largely attributable to its
Medicare program and the federal/state Medicaid program, which funds health care
for the needy. Recoveries were also obtained for the Office of Personnel
Management, which administers the Federal Employees Health Benefits Program, the
Department of Defense for its TRICARE insurance program, the Department of
Veterans Affairs, and others.

The largest health care recoveries came from pharmaceutical companies and
related entities. Settlements with Bristol-Myers Squibb Co., Aventis
Pharmaceuticals, Inc., Medco Health Solutions, Inc., Purdue Pharma L.P. and
Purdue Frederick Co., and InterMune, Inc. accounted for more than $800 million
of the $1.5 billion. In addition to federal recoveries, pharmaceutical fraud
cases returned $264 million to state Medicaid programs.

The Civil Division’s investigation of the pharmaceutical industry is part of a
Department-wide effort. Typical allegations involve illegal promotion of drugs
or devices and causing the government to pay for uses that were neither found by
the Food and Drug Administration to be safe and effective, nor supported by the
medical literature, also known as “off-label” marketing; paying kickbacks to
physicians, wholesalers, and pharmacies to induce drug or device purchases;
establishing inflated drug prices knowing that federal health care programs use
these prices to reimburse providers, then marketing the “spread” between the
federal reimbursement and the provider’s lower cost to induce drug purchases;
and failing to report the company’s true “best price” for a drug to reduce
rebates owed to the Medicaid program.

Outside the health care arena, fraud against the Department of
Defenseaccounted for $48.4 million in settlements. In cases involving other
agencies, Burlington Resources, Inc., a subsidiary of Conoco Phillips, paid the
United States $105.3 million based on claims that it had underpaid natural gas
royalties to the Department of Interior. In a record General Services
Administration settlement, Oracle Corporation paid the government $98.5 million
to resolve allegations that PeopleSoft, Inc. (acquired by Oracle in 2005)
engaged in defective pricing of its software and services under the company’s
multiple award schedule with GSA. And Mellon Bank, N.A. paid the United States
$34.6 million to settle claims that it violated its contract with the Internal
Revenue Service to process individual income tax returns and payments.

The Department also achieved favorable verdicts after lengthy trials in two
cases. The United States won a $172 million judgment against Amerigroup,
Illinois Inc. based on claims that Amerigroup’s HMO in Illinois illegally
increased its profits by discriminating against pregnant women and individuals
with pre-existing medical conditions when enrolling Medicaid-eligible
applicants. Amerigroup is appealing the jury’s verdict. In the second case, the
United States won a $90 million judgment against several companies for
conspiring to rig bids on contracts financed by the U.S. Agency for
International Development for the construction of wastewater treatment
facilities in Cairo, Egypt.

FACT SHEET: SIGNIFICANT RECOVERIES IN FISCAL YEAR 2007

Among the Department’s most significant settlements and judgments in fiscal
year 2007 were:
$328 million from Bristol-Myers Squibb Company (BMS) and its generic division,
Apothecon, to resolve a broad array of allegations involving illegal drug
pricing and marketing activities. BMS and Apothecon paid an additional $187
million to state Medicaid programs based on the same allegations. The civil
settlement arises from seven qui tam actions and resolves allegations that (1)
BMS and Apothecon set and maintained inflated prices knowing that federal health
care programs used these prices for reimbursement, and then marketed the
“spread”–the difference between the reported price and cost–to induce sales by
increasing providers’ profits; (2) BMS paid kickbacks to doctors in the form of
bogus consulting fees to induce them to purchase BMS’s drugs; (3) BMS paid
kickbacks to wholesalers and retail pharmacies to induce purchases of generic
products; (4) BMS promoted its atypical antipsychotic drug, Abilify, for
juvenile use and to treat dementia related psychosis–uses that were not approved
by the Food and Drug Administration; and (5) BMS violated the Medicaid Drug
Rebate Act, 42 U.S.C. § 1396r-8, by reporting false "best prices" to the
government for its drug Serzone, which resulted in BMS underpaying quarterly
rebates owed to the Medicaid program. The six relators will share a $52 million
award plus additional amounts from the states.

$311 million from four manufacturers of hip and knee surgical implant products–
Zimmer, Inc., Depuy Orthopaedics, Inc., Biomet Inc., and Smith & Nephew, Inc.–to
settle claims that from at least 2002 through 2006 these companies used
consulting agreements with orthopedic surgeons to induce the purchase of their
devices. The government's investigation revealed that the firms paid surgeons
hundreds of thousands of dollars a year for consulting contracts and lavished
them with trips and other expensive perquisites in exchange for using the
companies’ products exclusively. In addition to the civil settlements, the four
companies executed deferred prosecution agreements requiring new corporate
compliance procedures and the appointment of federal monitors to review their
compliance with these procedures.

$180 million from Aventis Pharmaceuticals, Inc. to resolve allegations that the
company engaged in a scheme (1) to set and maintain fraudulent and inflated
prices for its drug, Anzemet, knowing that federal health care programs
established reimbursement rates based on those prices, and (2) to use the
difference between the inflated prices reported and the actual prices charged to
its customers to market, promote, and sell the drug. In addition, Aventis paid
$10 million to several state governments based on the same allegations. The
relators shared a $33 million award.

$172 million judgment after trial against Amerigroup, Illinois Inc. finding
that Amerigroup fraudulently skewed enrollment in its Medicaid HMO program by
refusing to register pregnant women and by discouraging registration by
individuals with pre-existing conditions. Amerigroup had entered into contracts
with the Illinois Department of Public Health requiring the company to provide
health care services to Medicaid eligible individuals in Illinois. In violation
of these contracts, Amerigroup engaged in a cherry-picking scheme to ensure that
those who enrolled in its HMO program represented a disproportionately healthy
population of Medicaid-eligible individuals. As a result, Amerigroup reduced
its medical losses and increased its profits. Amerigroup has appealed the
judgment.

$155 million from Medco Health Solutions, Inc. to settle allegations that Medco
submitted false claims in connection with the mail order prescription drug
benefit offered under the Federal Employee Health Benefits Program. The
government alleged that Medco cancelled prescriptions it could not fill timely
to avoid late penalties, shorted pills, and billed for pharmacy services it
didn’t provide. The government also alleged that Medco solicited kickbacks from
pharmaceutical manufacturers to favor their drugs on Medco’s formulary, and paid
kickbacks to health plans to obtain business. The settlement resolved two qui
tam lawsuits and a separate federal investigation prompted by Medco’s disclosure
to the government concerning billing problems for diabetic supplies. The
relators received $23.9 million as their award. Medco also entered into a
corporate compliance agreement with the Department of Health and Human Services
and the Office of Personnel Management.

$100.6 million ($109 million including interest) from Purdue Pharma L.P. and
Purdue Frederick Company, Inc. to settle allegations of fraud against Medicaid
and other federal health care programs. The government alleged that Purdue
fraudulently misbranded OxyContin as being less addictive and less subject to
abuse and diversion than other pain medications. The civil settlement resolved
allegations that, based on these misleading marketing claims, Purdue knowingly
caused the submission of false claims for OxyContin that were not eligible for
federal reimbursement. In addition, Purdue paid $60 million to state Medicaid
programs, forfeited $276 million to the United States, set aside $130 million to
resolve private civil claims (with unclaimed amounts to revert to the United
States), paid $5.3 million to the Virginia Attorney General’s Medicaid Fraud
Control Unit to fund future health care fraud investigations, and paid $20
million to fund the Virginia Prescription Monitoring Program. Finally, Purdue
paid $500,000 in criminal fines–the maximum allowed under the statute.

$97.5 million ($105.3 million including interest) from Burlington Resources,
Inc., a subsidiary of Conoco Phillips, the third largest integrated energy
company in the United States, to settle claims that Burlington underpaid
royalties owed on natural gas produced under federal and Indian leases. The
government alleged that Burlington systematically underreported the value of the
natural gas it produced under onshore federal and Indian leases from March 1,
1988, to March 31, 2005, to reduce its obligation to pay royalties to the United
States and Indian tribes.

$98.5 million from Oracle Corporation, in a record fraud settlement involving
the General Services Administration (GSA), to resolve allegations that
PeopleSoft Inc., which was acquired by Oracle in 2005, violated the False Claims
Act. The allegations arose from a qui tam suit filed by a former employee of
PeopleSoft, who alleged that PeopleSoft provided GSA with pricing disclosures
for its software and related maintenance services that were not complete,
accurate and current. As a result of the defective disclosures, federal agencies
that purchased PeopleSoft software and services between March 17, 1997, and
September 30, 2005, under the company’s multiple award schedule with GSA, paid
inflated prices. The relator received $17.7 million as his statutory award.

$90 million judgment after trial against Harbert International, Inc.; Bill
Harbert International Construction, Inc.; Bilhar International Establishment
f/k/a Harbert International Establishment, a Liechtenstein company; and Harbert
Corporation. Harbert Construction Services (U.K.) Ltd., a British company, and
Elmore Roy Anderson are also liable for portions of the judgment. Following a
seven-week trial, a jury found the defendants liable for conspiracy to rig bids
on contracts to construct wastewater treatment facilities in Cairo, Egypt.
These contracts were financed by the U.S. Agency for International Development.
The jury found damages of $34 million. Pursuant to the False Claims Act, the
court trebled the amount of damages and added a $10,000 penalty for each of 111
false claims. The final award was reduced by amounts previously received by the
government in settlement with the defendants’ co-conspirators: J. A. Jones
Construction Company; Philipp Holzmann A.G., a German company; ABB SUSA, Inc.;
Archirodon Group, Inc.; and Bilfinger + Berger Bauaktiengesellschaft, a German
company. The relator’s award has yet to be determined.

$42.65 million to settle allegations of fraud against Maximus, Inc. in
connection with claims to the Medicaid program. The District of Columbia Child
and Family Services Agency (CFSA) hired Maximus to assist it in submitting
claims to Medicaid for targeted case management services provided by the
District to children in its foster care program. The United States alleged that
Maximus caused CFSA to submit claims for every child in the foster care program
whether or not targeted case management services had been provided to the child.
Maximus also entered into a deferred prosecution agreement with the U.S.
Attorney’s Office. The relator, a former division manager with Maximus,
received $4.93 million as his share of the recovery.

$34.6 million from Mellon Bank, N.A., to resolve allegations that the bank
violated the False Claims Act when in April, 2001, several of its employees hid
and then destroyed approximately 77,000 individual income tax returns, together
with approximately $1.3 billion in tax payment checks, instead of processing the
returns and checks as required by its Lockbox Depositary Agreement with the
Internal Revenue Service (IRS). Through a massive effort lasting more than a
year, the IRS was able to obtain copies of the tax returns and replacement
checks from most of the taxpayers. Although Mellon Bank had paid IRS for its
costs and for interest on the destroyed tax revenue, the out-of-court settlement
resolved the government’s claim that the bank was liable for multiple damages
and civil penalties under the False Claims Act.

$30.2 million from InterMune, Inc. to resolve allegations that InterMune
marketed its drug, Actimmune, for uses not approved by the Food and Drug
Administration resulting in federal health program losses. The government
alleged that InterMune marketed Actimmune for idiopathic pulmonary fibrosis
(IPF), a fatal disease that causes scarring of lung tissue. Although the
company had failed to demonstrate Actimmune’s efficacy for IPF, it nevertheless
misled physicians and the public to believe that the drug trial had been
successful. The relator received $5.7 million as her share of the recovery.
InterMune paid an additional $6.7 million to state Medicaid programs.